Abstract
Nasal absorption of tetracosactide (ACTH1−24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration. The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers. Tetracosactide plasma levels were monitored with radioimmunoassay. Nasal bioavailability was low (4.4%) compared to i.m. (24%). Poloxamer 407 addition did not improve drug kinetics profiles and showed a nonsignificant decrease in bioavailability (4%). On the other hand, both enhancers effectively increased tetracosactide nasal absorption. The sodium glycocholate effect was very fast (T max = 5 min), but did not last long. Moreover, absorption was increased threefold compared to the simple formulation. On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
P. D. Gesellchen and R. F. Santerre. Synthesis of peptides and proteins by chemical and biotechnological means. In V. H. L. Lee (ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 57–135.
P. Wüthrich and P. Buri. Doelker. Aspects de l'anatomie et de la physiologie nasale. Pharm. Acta Helv. 64:322–331 (1989).
E. Doelker. Innover pour réussir. J. Suisse Pharm. 18:490–495 (1991).
A. S. Harris. Biopharmaceutical aspects on the intranasal administration of peptides. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs, Plenum Press, New York, 1986, pp. 191–204.
C. McMartin, L. E. F. Hutchinson, R. Hyde, and G. E. Peters. Analysis of structural requirement for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76:535–540 (1987).
R. C. Gaillard. Régulateurs de la fonction hypothalamohypophysaire. In M. Schorderet (ed.), Pharmacologie, Des concepts fondamentaux aux applications thérapeutiques, Slatkine, Genève, 1988, pp. 433–436.
J. Juhasz, C. Pimienta, and V. Lenaerts. Adhesion of poloxamer 407 formulations on dog ileal segments in vitro. Eur. J. Pharm. Biopharm. 37:262–265 (1991).
Y. W. Chien and S. F. Chang. Historic development of transnasal systemic medications. In Y. W. Chien (ed.), Transnasal Systemic Medications, Elsevier, Amsterdam, 1985, pp. 1–99.
S. T. Anik and M. Johnson. Preformulation and formulation considerations of peptide drugs: Case history of an LHRH analog. In V. H. L. Lee (ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 57–135.
S. C. Raehs, J. Sandow, K. Wirth, and H. P. Merkle. The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm. Res. 5:689–693 (1988).
M. Normand, J. Lalonde, and N. Barden. Studies and dynamics of adrenocortical responses to ACTH in the rat. Mol. Cell Endocrinol. 27:97–106 (1982).
S. Hirai, Y. Yashiki, T. Matsuzawa, and H. Mima. Absorption of drugs from the nasal mucosa of rat. Int. J. Pharm. 7:317–325 (1981).
Users Guide for ACTH-RIA-100® Detection Kit, Medgenix, Belgium, 1986.
G. M. Besser, D. N. Orth, W. E. Nicholson, R. L. Byyny, K. Abe, and J. P. Woodham. Dissociation of the disappearance of bioactive and radioimmunoactive ACTH from plasma in man. J. Clin. Endocrinol. 32:595–603 (1971).
J. B. R. McKendry, H. Schwartz, and M. Hall. Intranasal corticotropin—its physiological and clinical effects. Can. Med. Assoc. J. 70:244–248 (1954).
W. J. Jeffcoate, C. Phenekos, J. G. Ratcliffe, S. Williams, L. Rees, and G. M. Besser. Comparison of the pharmacokinetics in man of two synthetic ACTH analogues: Alpha1–24 and substituted alpha1–18 ACTH. J. Clin. Endocrinol. 7:1–11 (1977).
T. Ohwaki, H. Ando S. Watanabe, and Y. Miyake. Nasal absorption of secretin in rats. In M. H. Rubinsten (ed.), Pharmaceutical Technology. Controlled Drug Release, Vol. 1, Ellis Horwood, Chichester, 1987, pp. 72–81.
K. Ebbens, C. Mastri, and M. Keplinger. Technical Bulletin, Pluronic Polyols Toxicity and Irritation Data, 3rd ed., rev., BASF Wyandotte Corp., 1973.
J. E. F. Reynolds. Martindale. The Extra Pharmacopoeia, 29th ed., Pharmaceutical Press, London, 1989.
J. Juhasz, V. Lenaerts, P. Raymond, and H. Ong. Diffusion of rat atrial natriuretic factor in thermoreversible poloxamer gels. Biomaterials 10:265–268 (1989).
Ch. K. Oh, G. A. Christensen, M. J. Reginato, R. A. Macia, and J. K. Vora. Effect of intranasal formulation variables on pharmacologic availability of growth hormone releasing peptide. Abstract book of the 2nd European Symposium on Controlled Drug Delivery, Noordwijk aan Zee, 1992, pp. 75–76.
R. DePoni and E. Lardini, Use of chemical enhancers for nasal drug delivery Drug Dev. Ind. Pharm. 17:1419–1436 (1991).
G. P. Martin, L. M. El-Hariri, and C. Marroitt. Bile salt-and lysophosphatidylcholine-induced membrane damage in human erythrocytes. J. Pharm. Pharmacol. 44:646–650 (1992).
H. M. Behre, J. Sandow, and E. Nieschlag. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men. Arzneim. Forsh./Drug Res. 42:80–84 (1992).
S. C. Raehs. Cyclopeptide zur Förderung der nasalen Absorption von Peptidarzneistoffen, Ph.D. thesis, Bonn, 1989.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wüthrich, P., Martenet, M. & Buri, P. Effect of Formulation Additives upon the Intranasal Bioavailability of a Peptide Drug: Tetracosactide (ACTH1−24). Pharm Res 11, 278–282 (1994). https://doi.org/10.1023/A:1018915710318
Issue Date:
DOI: https://doi.org/10.1023/A:1018915710318